|
|
 |
|
|
|
Abstract Categories
New and revised
1. HIV Dynamics & Evolution
1.1 Dynamics of the HIV epidemic
1.2 Molecular epidemiology
1.3 HIV diversity
1.4 Viral dynamics and fitness
1.5 HIV incidence measurement
1.6 Surveillance in resource-limited settings
1.7 Modelling the HIV epidemic
1.8 Morbidity/mortality in the era of HAART
2. Virology
2.1 HIV-1 and HIV-2
2.2 SIV and HIV-related viruses
2.3 Attachment,receptors,co-receptors,
entry,tropism
2.4 Reverse transcription
2.5 Integration
2.6 Regulation of HIV transcription
2.7 Maturation,morphogenesis and
assembly
2.8 Viral accessory genes
3. Immunology
3.1 HIV-induced immune dysfunction
and activation
3.2 Cellular suppressive factors
3.3 Innate immunity
3.4 HIV-specific humoral immunity
3.5 HIV-specific cellular immunity
3.6 HIV-specific mucosal immunity
3.7 T-cell homeostasis
3.8 Determinants of protection
3.9 Immune reconstitution
4. Pathogenesis
4.1 Biology of transmission
4.2 Primary infection
4.3 MHC and host genetic factors
4.4 Host regulatory genes
4.5 Long-term non-progressors
4.6 Mechanisms of CD4 T-cell depletion
4.7 Dendritic cells in HIV pathogenesis
4.8 HIV-induced apoptosis
4.9 Cytokines in HIV pathogenesis
4.10 Compartments of viral spreading
4.11 Anatomical and cellular reservoirs
4.12 Biological markers for monitoring
disease progression and therapy
5. Antiretroviral Therapy
5.1 New antiretroviral targets and
compounds
5.2 Clinical trials of new drugs/pro-drugs
5.3 Phase III/IV trials
5.4 Treatment of primary HIV infection
5.5 Initiation of therapy
5.6 Treatment failure and salvage therapy
5.7 Treatment simplification
5.8 Treatment interruption
5.9 Immunologic and virologic limitations
of HAART
5.10 Treatment of HIV-2
6. Treatment in Resource-Limited
Settings
6.1 Access to care
6.2 Models of treatment and care in diverse
settings
6.3 Prices of drugs
6.4 Strategies for delivery
6.5 Cost-benefit of HAART
6.6 Monitoring therapy
6.7 Operational research
6.8 Adverse events
6.9 Cultural issues
7. Immune-based Therapies and
Therapeutic Vaccines
7.1 IL-2
7.2 Therapeutic vaccination
7.3 Other immune-based therapies
8. Resistance
8.1 Resistance surveillance
8.2 Mechanisms of drug resistance
8.3 Genotyping and phenotyping
8.4 Resistance testing in clinical practice
9. Pharmacology and Drug
Interactions
9.1 PK and pharmacodynamics
9.2 Pharmacological monitoring
of ARV therapy
9.3 Drug interactions
9.4 Pharmacogenomics
9.5 Pharmacovigilance
10. Complications of Antiretroviral
Therapy
10.1 Metaanalysis of adverse events in
different settings
10.2 Lipids,and metabolic complications
10.3 Lipoatrophy
10.4 Mitochondrial toxicities
10.5 Cardiovascular risks
10.6 Liver toxicities
10.7 Other toxicities
10.8 Managing the side effects
11.Impact of Antiretroviral Therapy
11.1 Adherence
11.2 Impact of therapy on sexuality
11.3 Cultural issues
12.Tuberculosis
13. Opportunistic Diseases
13.1 Mycobacterial diseases other than
tuberculosis
13.2 Parasitic diseases
13.3 Fungal diseases
13.4 Bacterial diseases
13.5 CMV
13.6 HHV-8 and Kaposi ’s sarcoma
13.7 Non-Hodgkin ’s lymphomas
13.8 HPV
13.9 Impact of OI ’s on ARV treatment
strategies
14.Co-infections
14.1 Hepatitis viruses
14.2 Plasmodium
14.3 HIV and STD interactions
14.4 Other co-infections
15. Mother-to-Child Transmission
15.1 Epidemiology of vertical transmission
15.2 Perinatal transmission
15.3 Post-natal transmission
15.4 Clinical trials
15.5 Socio-behavioral aspects of MTCT
prevention
15.6 MTCT-Plus
16. Pediatrics
16.1 Pathogenesis of HIV disease in children
16.2 Pediatric treatment strategies
16.3 Clinical trials
16.4 Complications of ARV in children
16.5 Adolescent issues
17. Prevention of Horizontal
Transmission
17.1 Determinants of transmissibility
17.2 Prevention of sexual transmission
17.3 Post-exposure prophylaxis
17.4 Harm reduction and IVDU-related
strategies
17.5 Microbicides
18. Epidemiology and Infection
Control
18.1 Occupational transmission
18.2 Blood safety
18.3 IV drug use
18.4 Voluntary counselling and testing
18.5 Public health issues in developing
countries
18.6 Diagnostics
19. Preventive Vaccines
19.1 HIV vaccine strategies
19.2 Vectors and adjuvants
19.3 Mucosal vaccination
19.4 Genotypes and immunotypes
19.5 Monitoring anti-HIV immune responses
19.6 Animal models
19.7 Clinical trials
19.8 Modelling the impact of vaccines
19.9 New concepts in preventive vaccines
|
|
|
|
|
